During the last session, Apogee Therapeutics Inc (NASDAQ:APGE)’s traded shares were 0.52 million, with the beta value of the company hitting 2.53. At the end of the trading day, the stock’s price was $43.46, reflecting an intraday gain of 1.40% or $0.6. The 52-week high for the APGE share is $72.29, that puts it down -66.34 from that peak though still a striking 62.29% gain since the share price plummeted to a 52-week low of $16.39. The company’s market capitalization is $2.54B, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 404.91K shares over the past three months.
Apogee Therapeutics Inc (NASDAQ:APGE) trade information
Apogee Therapeutics Inc (APGE) registered a 1.40% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.40% in intraday trading to $43.46, hitting a weekly high. The stock’s 5-day price performance is -8.02%, and it has moved by -16.34% in 30 days. Based on these gigs, the overall price performance for the year is 152.23%. The short interest in Apogee Therapeutics Inc (NASDAQ:APGE) is 6.81 million shares and it means that shorts have 20.47 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target of analysts on Wall Street is $95, which implies an increase of 54.25% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $95 and $95 respectively. As a result, APGE is trading at a discount of -118.59% off the target high and -118.59% off the low.
Apogee Therapeutics Inc (APGE) estimates and forecasts
Statistics show that Apogee Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Apogee Therapeutics Inc (APGE) shares have gone down -9.51% during the last six months, with a year-to-date growth rate less than the industry average at 16.37% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -242.19% this quarter and then drop -87.50% in the quarter after that.
While earnings are projected to return 7.64% in 2024.
APGE Dividends
Apogee Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Apogee Therapeutics Inc (NASDAQ:APGE)’s Major holders
Apogee Therapeutics Inc insiders own 11.71% of total outstanding shares while institutional holders control 127.23%, with the float percentage being 144.11%.
Also, the Mutual Funds coming in first place with the largest holdings of Apogee Therapeutics Inc (APGE) shares are Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund . Data provided on Jul 31, 2024 indicates that Vanguard Specialized-Health Care Fund owns about 1.57 shares. This amounts to just over 3.48 percent of the company’s overall shares, with a $68.19 million market value. The same data shows that the other fund manager holds slightly less at 1.43, or about 3.18% of the stock, which is worth about $62.14 million.
